Pre-market hot trades in the US stock market: Office Properties Income Trust pre-market down 9.14%; Turbo Energy SA pre-market up 9.05%
I'm LongbridgeAI, I can summarize articles.Office Properties Income Trust pre-market down 9.14%; Turbo Energy SA pre-market up 9.05%; 89bio pre-market up 85.02%; Psyence Biomedical pre-market up 70.70%; Aptevo Therap pre-market up 66.67%
Pre-market Hot Trades in US Stocks
Office Properties Income Trust is down 9.14% in pre-market trading. According to recent key news:
-
On September 18, Office Properties Income Trust considered filing for bankruptcy, leading to a 29% drop in stock price. The company faces over $900 million in debt maturity pressure. Source: 9fin.com
-
On September 17, technical analysis showed a bearish trend, with poor valuation indicators, a negative price-to-earnings ratio, and a suspension of dividends, resulting in a low overall stock rating.
Top Gainers in Pre-market US Stocks
89bio is up 85.02% in pre-market trading based on the latest important news:
-
On September 18, Roche announced it would acquire 89bio for $14.50 per share in cash, with a total equity value of approximately $2.4 billion. Including contingent value rights, the total transaction value could reach up to $3.5 billion. This news significantly boosted 89bio's stock price.
-
On September 18, Roche stated that 89bio's key drug pegozafermin is expected to become the best therapy for treating moderate to severe metabolic dysfunction-associated fatty liver disease (MASH), further enhancing market confidence in 89bio.
-
On September 18, Roche's recent transactions have all been related to obesity, indicating its strategic positioning in this field, which further raised investor expectations for 89bio. The biopharmaceutical industry has seen frequent M&A activity recently, attracting high market attention.
Aptevo Therapeutics is up 66.67% in pre-market trading based on recent key news:
-
On September 16, Aptevo Therapeutics announced that the third cohort of its Phase 1b/2 RAINIER trial for acute myeloid leukemia (AML) achieved a 100% remission rate, leading to a 57% increase in stock price. The study tested Aptevo's CD123 x CD3 bispecific antibody in combination with venetoclax and azacitidine for newly diagnosed AML patients.
-
On September 16, Aptevo's trading volume surged, with approximately 34 million shares changing hands, compared to an average daily trading volume of about 165,000 shares over the past three months, indicating a strong market reaction to the news.
-
On September 17, despite challenges in Aptevo's financial performance, positive progress in its oncology pipeline provides potential upside for the future. The biotechnology industry is highly volatile and requires caution